Bushra Imtiaz, Heidi Taipale, Antti Tanskanen, Miia Tiihonen, Miia Kivipelto,  Anna-Mari Heikkinen,  Jari Tiihonen,  Hilkka Soininen,  Sirpa Hartikainen,  Anna-Maija Tolppanen

Highlights

• •A history of systemic estrogen and progestogen use was more common among people with Alzheimer’s disease (19.3% and 11.4%) than controls (17.7% and 10.3%).
• •Shorter duration of estrogen use was associated with a modestly increased risk of Alzheimer’s disease, and longer duration with a weakly decreased risk.
• •Hormone therapy was not an important determinant of risk of Alzheimer’s disease in this nationwide case-control study.

Abstract

Objective

To examine the association between postmenopausal hormone therapy (HT) and Alzheimer’s disease (AD).

Methods

Medicine and Alzheimer’s disease (MEDALZ) is a nested case-control study of the entire Finnish population with clinically verified AD from 2005 to 2011 and up to 4 matched controls per case. This study comprises 230,580 women (46,117 cases and 184,463 controls). Data on HT use from 1995 to 2011 was extracted from the national prescription register using following ATC codes: G03C (estrogen), G03D (progestogen) and G03F (estrogen and progestogen in combination). Only systemic HT (oral or transdermal) was considered.

Results

Use of systemic estrogen and progestogen was associated with an increased risk of AD, with ORs (95% CI) of 1.10 (1.06–1.12) and 1.13 (1.10–1.17) respectively, but use of systemic estrogen HT for >10 years (OR, 95% CI: 0.91, 0.84–0.99) was protective against AD. Long-term (>10 years) use of progestogen and combination HT was not related to AD risk (OR, 95% CI: 1.0, 0.90–1.2).

Conclusion

Our findings do not suggest HT is an important determinant of AD risk.

DOI: http://dx.doi.org/10.1016/j.maturitas.2017.01.002

資料來源：Maturitas